Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena.
Equilibrium binding studies on the interaction between the anthracycline daunomycin and plasma membrane fractions from daunomycin-sensitive and -resistant murine leukemia P-388 cells are presented. Drug binding constants (KS) are 15,000 and 9800 M-1 for plasma membranes from drug-sensitive and drug-resistant cells, respectively. Drug binding to the membranes is not affected by either (i) thermal denaturation of membrane proteins or (ii) proteolytic treatment with trypsin, thus suggesting that the protein components of the membranes do not have a major role in determining the observed drug binding. Also, fluorescence resonance energy transfer between tryptophan and daunomycin in the membranes indicates that interaction of protein components with the drug should not be responsible for the observed differences in drug binding exhibited by plasma membranes from drug-sensitive and -resistant cells. Plasma membranes from drug-sensitive cells contain more phosphatidylserine and slightly less cholesterol than membranes from drug-resistant cells. Differences in the content of the acidic phospholipid between the two plasma membranes seem to produce a different ionic environment at membrane surface domains, as indicated by titration of a membrane-incorporated, pH-sensitive fluorescence probe. The possible role of membrane lipids in modulating drug binding to the membranes was tested in equilibrium binding studies using model lipid vesicles made from phosphatidylcholine, phosphatidylserine, and cholesterol in different proportions. The presence of phosphatidylserine greatly increases both the affinity and the stoichiometry of daunomycin binding to model lipid vesicles. The similarity between the effects of phosphatidylserine and other negatively charged compounds such as dicetyl phosphate, cardiolipin, or phosphatidic acid suggests that electrostatic interactions are important in the observed binding of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)
Escriba
P V
PV
Department of Neurochemistry, School of Medicine, University of Alicante, Spain.
Ferrer-Montiel
A V
AV
Ferragut
J A
JA
Gonzalez-Ros
J M
JM
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism*; D003630:Daunorubicin / Q000378:metabolism*; D004351:Drug Resistance; D007941:Leukemia P388 / Q000378:metabolism; D008081:Liposomes; D008563:Membrane Lipids / Q000502:physiology*; D051379:Mice; D010743:Phospholipids / Q000502:physiology; D014407:Tumor Cells, Cultured / Q000378:metabolism*
D000970:Antineoplastic Agents; D008081:Liposomes; D008563:Membrane Lipids; D010743:Phospholipids; D003630:Daunorubicin